Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michaela C Barbier"'
Autor:
Michaela C Barbier, Yuki Tomonaga, Dominik Menges, Henock G Yebyo, Sarah R Haile, Milo A Puhan, Matthias Schwenkglenks
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0277282 (2022)
BackgroundIn metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen depri
Externí odkaz:
https://doaj.org/article/95228d3593c848d08f1aab9ad6994784
Autor:
Dominik Menges, Henock G. Yebyo, Sergio Sivec-Muniz, Sarah R. Haile, Michaela C. Barbier, Yuki Tomonaga, Matthias Schwenkglenks, Milo A. Puhan
Publikováno v:
European Urology Oncology. 5:605-616
Multiple treatments for metastatic, hormone-sensitive prostate cancer (mHSPC) are available, but their effects on health-related quality of life (HRQoL) and benefit-harm balance remain unclear.To assess clinical effectiveness regarding survival and H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90936ecdd42fdc564d6d12739e68f2e0
https://doi.org/10.1016/j.euo.2022.04.007
https://doi.org/10.1016/j.euo.2022.04.007
Autor:
Michaela C. Barbier, Yuki Tomonaga, Dominik Menges, Henock G. Yebyo, Sarah R. Haile, Milo A. Puhan, Matthias Schwenkglenks
Background In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen depr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b05e49252bca9695ca66e39c0e24be4
https://www.zora.uzh.ch/id/eprint/226005/
https://www.zora.uzh.ch/id/eprint/226005/
